FOLD Amicus Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Amicus Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Amicus Therapeutics, Inc. (“Amicus Therapeutics” or the “Company”) (NASDAQ: FOLD) concerning possible violations of federal securities laws by certain officers and directors.

On November 28, 2016, Amicus Therapeutics shares fell after hours following an announcement that the Food and Drug Administration will not grant an accelerated approval for its drug migalastat to treat Fabry disease. Shares of Amicus Therapeutics were down more than 21% on intraday trading on November 29, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/amicus-therapeutics-fold

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
29/11/2016

Underlying

FOLDAmicus Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Third Quarter 2025 Financial Results an...

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2025. “Amicus achieved yet another impressive qu...

November 4, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Nov...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ETJefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMT A live audio webcast of each presentation can also be accessed via the investors se...

October 31, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results o...

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the eve...

October 23, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® ...

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of M...

September 8, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Sep...

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET A live audio webcast of each presentation can also be accessed via ...

August 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch